LifeMD, Inc.

On August 22, 2025, Eric Yecies, Chief Legal Officer and General Counsel, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 200,000 shares of the Company’s common stock, at various limit prices above the current market price of the Company’s common stock as of the plan adoption date, with such transactions to occur during sale periods beginning on or after November 21, 2025 and ending on the earlier of December 31, 2026 or the date on which all shares authorized for sale have been sold in conformance with the terms of the arrangement.

As described in Part 1, Item 4. Controls and Procedures, we have identified an additional material weakness in our internal control over financial reporting as of September 30, 2025. We have concluded that this material weakness also existed as of December 31, 2024, March 31, 2025 and June 30, 2025. Accordingly, the previous conclusion included in Item 9A of our Form 10-K filed with the Securities and Exchange Commission on March 11, 2025 that our disclosure controls and procedures and internal control over financial reporting were ineffective is hereby updated to include this additional material weakness. Also, the previous conclusions included in Item 4 of our Forms 10-Q filed with the Securities and Exchange Commission on May 6, 2025 and August 5, 2025 that our disclosure controls and procedures was ineffective is hereby updated to also include this additional material weakness.